Imago BioSciences, Inc. Operating Cash Flow
Imago BioSciences, Inc. reported Operating Cash Flow of -$39.00 million for the 9-month period ending 2022-09-30, per its 10-Q filed 2022-11-09.
Discontinued › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2022-11-09
- Imago BioSciences, Inc. net cash provided by (used in) operating activities for the quarter ending 2022-09-30 was -$11.72M.
- Imago BioSciences, Inc. net cash provided by (used in) operating activities for the quarter ending 2022-06-30 was -$15.77M.
- Imago BioSciences, Inc. net cash provided by (used in) operating activities for the quarter ending 2022-03-31 was -$11.52M.
- Imago BioSciences, Inc. net cash provided by (used in) operating activities for the quarter ending 2021-12-31 was -$13.29M.
- Imago BioSciences, Inc. net cash provided by (used in) operating activities for fiscal 2021 was -$39.76M.
- Imago BioSciences, Inc. net cash provided by (used in) operating activities for fiscal 2020 was -$16.94M.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 12 month |
|---|---|---|---|---|
| 2022-09-30 | -$11.72M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | -$27.48M derived: sum of 2 quarters · filed 2022-11-09 | -$39.00M 10-Q · filed 2022-11-09 | -$52.29M derived: sum of 4 quarters · filed 2022-11-09 |
| 2022-06-30 | -$15.77M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-12 | -$27.29M 10-Q · filed 2022-08-12 | -$40.58M derived: sum of 3 quarters · filed 2022-08-12 | -$52.80M derived: sum of 4 quarters · filed 2022-11-09 |
| 2022-03-31 | -$11.52M 10-Q · filed 2022-05-12 | -$24.81M derived: sum of 2 quarters · filed 2022-05-12 | -$37.04M derived: sum of 3 quarters · filed 2022-11-09 | -$44.23M derived: sum of 4 quarters · filed 2022-11-09 |
| 2021-12-31 | -$13.29M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-24 | -$25.52M derived: sum of 2 quarters · filed 2022-11-09 | -$32.71M derived: sum of 3 quarters · filed 2022-11-09 | -$39.76M 10-K · filed 2022-03-24 |
| 2021-09-30 | -$12.22M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | -$19.42M derived: sum of 2 quarters · filed 2022-11-09 | -$26.47M 10-Q · filed 2022-11-09 | -$31.32M derived: sum of 4 quarters · filed 2022-11-09 |
| 2021-06-30 | -$7.19M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-12 | -$14.25M 10-Q · filed 2022-08-12 | -$19.10M derived: sum of 3 quarters · filed 2022-08-12 | -$23.88M derived: sum of 4 quarters · filed 2022-08-12 |
| 2021-03-31 | -$7.05M 10-Q · filed 2022-05-12 | -$11.91M derived: sum of 2 quarters · filed 2022-05-12 | -$16.69M derived: sum of 3 quarters · filed 2022-05-12 | |
| 2020-12-31 | -$4.85M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-24 | -$9.63M derived: sum of 2 quarters · filed 2022-03-24 | -$16.94M 10-K · filed 2022-03-24 | |
| 2020-09-30 | -$4.78M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | -$12.09M 10-Q · filed 2021-11-10 | ||
| 2020-06-30 | -$7.31M 10-Q · filed 2021-08-19 |